Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS INDUSTRY
2.1 Summary about Benign Prostatic Hyperplasia (BPH) Drugs Industry
2.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
2.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production & Consumption Trends
2.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Demand Structure Trends
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 Alpha-blocker
4.2.2 Phosphodiesterase Type-5 Inhibitors
4.2.3 5-alpha-Reductase Inhibitors
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospitals
4.3.2 Clinics
4.3.3 Others
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 Alpha-blocker
5.2.2 Phosphodiesterase Type-5 Inhibitors
5.2.3 5-alpha-Reductase Inhibitors
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Others
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 Alpha-blocker
6.2.2 Phosphodiesterase Type-5 Inhibitors
6.2.3 5-alpha-Reductase Inhibitors
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospitals
6.3.2 Clinics
6.3.3 Others
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 Alpha-blocker
7.2.2 Phosphodiesterase Type-5 Inhibitors
7.2.3 5-alpha-Reductase Inhibitors
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospitals
7.3.2 Clinics
7.3.3 Others
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 Alpha-blocker
8.2.2 Phosphodiesterase Type-5 Inhibitors
8.2.3 5-alpha-Reductase Inhibitors
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospitals
8.3.2 Clinics
8.3.3 Others
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 Alpha-blocker
9.2.2 Phosphodiesterase Type-5 Inhibitors
9.2.3 5-alpha-Reductase Inhibitors
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospitals
9.3.2 Clinics
9.3.3 Others
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 Astellas Pharma
10.1.2 Eli Lilly
10.1.3 GlaxoSmithKline
10.1.4 Sanofi
10.1.5 ADC Therapeutics
10.1.6 Bayer HealthCare
10.1.7 Bristol-Myers Squibb
10.1.8 Valeant Pharmaceuticals
10.1.9 Endo Pharmaceuticals
10.1.10 Foresee Pharmaceuticals
10.1.11 Madrigal Pharmaceuticals
10.1.12 Merck
10.1.13 Novartis
10.1.14 Spectrum Pharmaceuticals
10.1.15 Takeda Pharmaceuticals
10.1.16 Teva
10.1.17 Advaxis
10.1.18 ANI Pharmaceuticals
10.1.19 BHR Pharma
10.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Date of Major Players (2017-2020e)
10.2.1 Astellas Pharma
10.2.2 Eli Lilly
10.2.3 GlaxoSmithKline
10.2.4 Sanofi
10.2.5 ADC Therapeutics
10.2.6 Bayer HealthCare
10.2.7 Bristol-Myers Squibb
10.2.8 Valeant Pharmaceuticals
10.2.9 Endo Pharmaceuticals
10.2.10 Foresee Pharmaceuticals
10.2.11 Madrigal Pharmaceuticals
10.2.12 Merck
10.2.13 Novartis
10.2.14 Spectrum Pharmaceuticals
10.2.15 Takeda Pharmaceuticals
10.2.16 Teva
10.2.17 Advaxis
10.2.18 ANI Pharmaceuticals
10.2.19 BHR Pharma
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT
